Denosumab – inhibitor of a key mediator in osteoclast formation – a new data

Osteoporotic fractures and the decline of quality of life related with them constitute a serious problem of patients of an old age. The treatment consisting in taking medicines constitute a significant part of the therapeutical process, that is why their adequate choice is so important. It should be linked with efficacy and appropriate safety profile. The promising treatment results by means of human monoclonal antibody seem to get nearer the solution of this problem. Denosumab is a monoclonal antibody combined with RANKL. This combination stops the creation of polymorphonuclear osteoclasts and the inhibition of the resorption process. Its application once every 6 months and a small number of adverse events create good conditions for an effective treatment.